Equillium, Inc. Common Stock
EQEquillium, Inc. (EQ) is a biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company specializes in novel immunotherapies that target the underlying immune mechanisms contributing to conditions such as transplantation rejection, autoimmune disorders, and inflammatory diseases.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 30, 2009 | $0.69 | 2009-06-12 | 2009-06-16 |
| March 31, 2009 | $0.69 | 2009-03-13 | 2009-03-17 |
| December 31, 2008 | $0.69 | 2008-12-08 | 2008-12-10 |
| September 30, 2008 | $0.69 | 2008-09-05 | 2008-09-09 |
| June 30, 2008 | $0.69 | 2008-06-05 | 2008-06-09 |
Dividends Summary
- Consistent Payer: Equillium, Inc. Common Stock has rewarded shareholders with 12 dividend payments over the past 3 years.
- Total Returned Value: Investors who held EQ shares during this period received a total of $7.50 per share in dividend income.
- Latest Payout: The most recent dividend of $0.69/share was paid 6227 days ago, on June 30, 2009.
- Yield & Schedule: EQ currently pays dividends quarterly with an annual yield of 106.18%.
- Dividend Growth: Since 2006, the dividend payout has grown by 37.5%, from $0.50 to $0.69.
- Dividend Reliability: EQ has maintained or increased its dividend for 12 consecutive payments.
Company News
Wereldhave Belgium has acquired a supermarket anchor unit in shopping center Ville2 in Charleroi, achieving 100% ownership of the property. The acquisition was financed through newly issued Wereldhave N.V. shares at market value and will have a slightly positive impact on the group's LTV ratio, reducing it by 10 basis points to 42.4%.
Equillium will host a virtual key opinion leader event discussing unmet needs in ulcerative colitis treatment, featuring experts who will explore the potential of AhR modulation and the company's EQ504 therapeutic approach.
Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.
The graft versus host disease market is experiencing significant growth, driven by the adoption of branded therapies, a strong pipeline with the anticipated launch of over 10 new drugs, and increased awareness of GvHD management. Innovative treatments and ongoing research are expected to further expand market opportunities.
Vivtex and Equillium have entered a research collaboration to develop an optimized oral version of Equillium's EQ302, a bi-specific peptide inhibitor of IL-15 and IL-21, for the treatment of gastrointestinal disorders.
